US EditionPublished • loading... • Updated
FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
The FDA's warnings target false marketing claims by Hims & Hers, while AstraZeneca halts a $270 million UK research investment due to a challenging business environment, Reuters reports.
- On Tuesday, the FDA issued more than 100 warning letters to various companies, including the telehealth provider Hims & Hers, addressing misleading marketing claims.
- The letters followed President Donald Trump's recent memo targeting direct-to-consumer drug ads and addressed telehealth companies promoting unapproved compounded weight-loss drugs.
- The FDA warned Hims & Hers that its website falsely implied its compounded products matched FDA-approved drugs like Wegovy and Ozempic, despite compounding only being permitted during drug shortages.
- Shares of Hims & Hers dropped over 6.47% on Tuesday amid the regulatory action and the FDA's use of 'cease and desist' language emphasized in the letters.
- This FDA crackdown signals increased regulatory scrutiny on telemedicine firms' marketing and may affect the growth of inexpensive compounded weight-loss drug sales.
Insights by Ground AI
29 Articles
29 Articles
The Billings Gazette+4 Reposted by 4 other sources
FDA targets Hims & Hers, unofficial medications
WASHINGTON — For the first time, federal health officials took aim at telehealth companies promoting unofficial versions of prescription drugs, part of the Trump administration’s crackdown on pharmaceutical advertising.
·Billings, United States
Read Full Article
Coverage Details
Total News Sources29
Leaning Left2Leaning Right0Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
L 20%
C 80%
Factuality
To view factuality data please Upgrade to Premium
